BACKGROUND: Grass pollen is one of the most important allergen sources. The aim of this study was to compare the in vivo allergenic activity of two recently characterized major grass pollen allergens, Phl p 4 and Phl p 13, with three established major grass pollen allergens, Phl p 1, Phl p 2 and Phl p 5 as a basis for the formulation of a grass pollen allergy vaccine based on purified allergens. MATERIAL AND METHODS: Eighty-two grass pollen allergic patients were skin prick tested with serial dilutions of approximately equimolar concentrations of the purified allergens in a double-blind study. RESULTS: Phl p 4 and Phl p 13 were identified as major grass pollen allergens according to IgE binding frequency (Phl p 4: 85%; Phl p 13: 56%), but exhibited a five to nine-fold lower allergenic skin reactivity compared to Phl p 1, Phl p 2 or Phl p 5. CONCLUSION: Our results indicate that Phl p 4 and Phl p 13 are not essential components for a therapeutic grass pollen vaccine and underpin the importance of evaluating the in vivo allergenic activity of individual allergens for the formulation of therapeutic vaccines based on purified allergens.
BACKGROUND: Grass pollen is one of the most important allergen sources. The aim of this study was to compare the in vivo allergenic activity of two recently characterized major grass pollen allergens, Phlp 4 and Phl p 13, with three established major grass pollen allergens, Phlp 1, Phl p 2 and Phlp 5 as a basis for the formulation of a grass pollen allergy vaccine based on purified allergens. MATERIAL AND METHODS: Eighty-two grass pollen allergicpatients were skin prick tested with serial dilutions of approximately equimolar concentrations of the purified allergens in a double-blind study. RESULTS:Phlp 4 and Phl p 13 were identified as major grass pollen allergens according to IgE binding frequency (Phlp 4: 85%; Phl p 13: 56%), but exhibited a five to nine-fold lower allergenic skin reactivity compared to Phlp 1, Phl p 2 or Phlp 5. CONCLUSION: Our results indicate that Phlp 4 and Phl p 13 are not essential components for a therapeutic grass pollen vaccine and underpin the importance of evaluating the in vivo allergenic activity of individual allergens for the formulation of therapeutic vaccines based on purified allergens.
Authors: Christoph Madritsch; Elisabeth Gadermaier; Uwe W Roder; Christian Lupinek; Rudolf Valenta; Sabine Flicker Journal: J Immunol Date: 2015-01-30 Impact factor: 5.422
Authors: T E Twaroch; M Focke; K Fleischmann; N Balic; C Lupinek; K Blatt; R Ferrara; A Mari; C Ebner; P Valent; S Spitzauer; I Swoboda; R Valenta Journal: Clin Exp Allergy Date: 2012-06 Impact factor: 5.018
Authors: E Wollmann; C Hamsten; E Sibanda; M Ochome; M Focke-Tejkl; A Asarnoj; A Önell; G Lilja; D Gallerano; C Lupinek; T Thalhamer; R Weiss; J Thalhamer; M Wickman; R Valenta; M van Hage Journal: Allergy Date: 2015-03-22 Impact factor: 13.146
Authors: S C Devanaboyina; C Cornelius; C Lupinek; K Fauland; F Dall'Antonia; A Nandy; S Hagen; S Flicker; R Valenta; W Keller Journal: Allergy Date: 2014-10-06 Impact factor: 13.146